208 related articles for article (PubMed ID: 6542006)
1. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
[TBL] [Abstract][Full Text] [Related]
2. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB
Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of mitoxantrone].
Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
Stuart-Harris RC; Smith IE
Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
Coleman RE; Maisey MN; Knight RK; Rubens RD
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):771-6. PubMed ID: 6540179
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Allegra JC; Woodcock T; Woolf S; Henderson IC; Bryan S; Reisman A; Dukart G
Invest New Drugs; 1985; 3(2):153-61. PubMed ID: 3894278
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Stuart-Harris RC; Bozek T; Pavlidis NA; Smith IE
Cancer Chemother Pharmacol; 1984; 12(1):1-4. PubMed ID: 6690066
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial.
Williams SD; Birch R; Velez-Garcia E; Gams R
Invest New Drugs; 1985; 3(3):311-3. PubMed ID: 4066226
[TBL] [Abstract][Full Text] [Related]
12. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.
Coltman CA; Coltman TM; Balcerzak SP; Morrison FS; Von Hoff DD
Semin Oncol; 1984 Sep; 11(3 Suppl 1):50-3. PubMed ID: 6484581
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone in malignant lymphoma.
Gams RA; Bryan S; Dukart G; Weiss A; Case D; Jones S; Stein R
Invest New Drugs; 1985; 3(2):219-22. PubMed ID: 4019123
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone.
Poirier TI
Drug Intell Clin Pharm; 1986 Feb; 20(2):97-105. PubMed ID: 3512224
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Metz R; Delgado M; Keiling R; Cappelaere P; Armand JP; Prevot G; Misset JL; Grimbert J; Mathe G
Invest New Drugs; 1985; 3(2):163-6. PubMed ID: 4019119
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Ford JM; Panasci L; Leclerc Y; Margolese R
Cancer Treat Rep; 1987 Oct; 71(10):921-5. PubMed ID: 3308079
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Wilson WH; Berg SL; Bryant G; Wittes RE; Bates S; Fojo A; Steinberg SM; Goldspiel BR; Herdt J; O'Shaughnessy J
J Clin Oncol; 1994 Aug; 12(8):1621-9. PubMed ID: 7913721
[TBL] [Abstract][Full Text] [Related]
19. First-line mitoxantrone chemotherapy for advanced breast cancer.
Wilson KS; Paterson AH
Cancer Treat Rep; 1986 Aug; 70(8):1021-2. PubMed ID: 3731148
[TBL] [Abstract][Full Text] [Related]
20. Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study.
Pratt CB; Vietti TJ; Etcubanas E; Sexauer C; Krance RA; Mahoney DH; Patterson RB
Invest New Drugs; 1986; 4(1):43-8. PubMed ID: 3700039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
